Download PDF
Semin Liver Dis 2004; 24(1): 3-20
DOI: 10.1055/s-2004-823098
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Nonalcoholic Steatohepatitis

Elizabeth M. Brunt1
  • 1Associate Professor of Pathology, Saint Louis University Liver Center, Saint Louis University Health Sciences Center, Department of Pathology, St. Louis, Missouri
Further Information

Publication History

Publication Date:
13 April 2004 (online)

    Permissions and Reprints

Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a common liver disorder that represents the hepatic manifestation of the metabolic syndrome, a variably defined aggregate of disorders related to obesity, insulin resistance, type II diabetes, hypertension and hyperlipidemia. Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC) is a documented complication in an as yet unknown percentage of cases of NASH cirrhosis. The diagnosis of nonalcoholic steatohepatitis requires histopathologic evaluation because the lesions of parenchymal injury and fibrosis cannot be detected by imaging studies or laboratory tests. This article will briefly discuss prevalence studies and the pathophysiology of NAFLD and focus on current discussions related to the specific lesions in the pathology of NASH, including the challenges of pediatric NASH and NASH-related cirrhosis.

KEYWORDS

Nonalcoholic fatty liver disease - nonalcoholic steatohepatitis - obesity - metabolic syndrome - insulin resistance

REFERENCES

  • 1 Sanyal A J. AGA technical review on nonalcoholic fatty liver disease.  Gastroenterology. 2002;  123 1705-1725
    CrossrefPubMedGoogle Scholar
  • 2 Neuschwander-Tetri B A, Caldwell S H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference.  Hepatology. 2003;  37 1202-1219
    CrossrefPubMedGoogle Scholar
  • 3 McCullough A J. Update on nonalcoholic fatty liver disease.  J Clin Gastroenterol. 2002;  34 255-262
    CrossrefPubMedGoogle Scholar
  • 4 Dixon J B, O'Brien P E, Bhatal P S. A wider view on diagnostic criteria of nonalcoholic steatohepatitis (reply).  Gastroenterology. 2002;  122 841-842
    PubMedGoogle Scholar
  • 5 Brunt E M. Nonalcoholic steatohepatitis: definition and pathology.  Semin Liver Dis. 2001;  21 3-16
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Ludwig J, Viggiano T R, McGill D B, Oh B J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.  Mayo Clin Proc. 1980;  55 434-438
    PubMedGoogle Scholar
  • 7 Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients.  Am J Med. 1979;  67 811-816
    CrossrefPubMedGoogle Scholar
  • 8 Nasrallah S M, Wills C E, Galambos J T. Hepatic morphology in obesity.  Dig Dis Sci. 1981;  26 325-327
    CrossrefPubMedGoogle Scholar
  • 9 Silverman J F, O'Brien K F, Long S et al.. Liver pathology in morbidly obese patients with and without diabetes.  Am J Gastroenterol. 1990;  85 1349-1355
    PubMedGoogle Scholar
  • 10 Silverman E M, Sapala J A, Appelman H D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass.  Am J Clin Pathol. 1995;  104 23-31
    PubMedGoogle Scholar
  • 11 Teli M R, James O FW, Burt A D, Bennett M K, Day C P. The natural history of nonalcoholic fatty liver-a follow-up study.  Hepatology. 1995;  22 1714-1719
    CrossrefPubMedGoogle Scholar
  • 12 Falck-Ytter Y, Younossi Z M, Marchesini G, McCullough A J. Clinical features and natural history of nonalcoholic steatosis syndromes.  Semin Liver Dis. 2001;  21 17-26
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Matteoni C A, Younossi Z M, Gramlich T et al.. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.  Gastroenterology. 1999;  116 1413-1419
    CrossrefPubMedGoogle Scholar
  • 14 Clark J M, Brancati F L, Diehl A M. Nonalcoholic fatty liver disease.  Gastroenterology. 2002;  122 1649-1657
    CrossrefPubMedGoogle Scholar
  • 15 Clark J M, Diehl A M. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies.  Gastroenterology. 2003;  124 248-250
    CrossrefPubMedGoogle Scholar
  • 16 Dixon J B, Bhathal P S, O'Brien P E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.  Gastroenterology. 2001;  121 91-100
    CrossrefPubMedGoogle Scholar
  • 17 Wigg A J, Roberts-Thomson I C, Dymock R B et al.. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis.  Gut. 2001;  48 206-211
    CrossrefPubMedGoogle Scholar
  • 18 Farrell G C. Is bacterial ash the flash that ignites NASH?.  Gut. 2001;  48 148-149
    CrossrefPubMedGoogle Scholar
  • 19 Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome-prevalence and determinants of a “bright” liver echopattern.  Ital J Gastroenterol Hepatol. 1997;  29 351-356
    PubMedGoogle Scholar
  • 20 Bellentani S, Sacciccio G, Masutti F et al.. Prevalence of and risk factors for hepatic steatosis in northern Italy.  Ann Intern Med. 2000;  132 112-117
    PubMedGoogle Scholar
  • 21 Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study.  J Hepatol. 2001;  35 531-537
    CrossrefPubMedGoogle Scholar
  • 22 Saadeh S, Younossi Z M, Remer E M et al.. The utility of radiological imaging in nonalcoholic fatty liver disease.  Gastroenterology. 2002;  123 745-750
    CrossrefPubMedGoogle Scholar
  • 23 Ruhl C E, Everhart J E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.  Gastroenterology. 2003;  124 71-79
    CrossrefPubMedGoogle Scholar
  • 24 Prati D, Taioli E, Zanella A et al.. Updated definitions of healthy ranges for serum alanine aminotransferase levels.  Ann Intern Med. 2002;  137 1-9
    CrossrefPubMedGoogle Scholar
  • 25 Expert panel on Detection . Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP).  JAMA. 2001;  285 2486-2497
    CrossrefPubMedGoogle Scholar
  • 26 Clark J M, Brancati F L, Diehl A M. The prevalence and etiology of elevated aminotransferase levels in the United States.  Am J Gastroenterol. 2003;  98 960-967
    CrossrefPubMedGoogle Scholar
  • 27 Kim W R, Brown R S, Terrault N A, El-Serag H. Burden of liver disease in the United States: summary of a workshop.  Hepatology. 2002;  36 227-242
    CrossrefPubMedGoogle Scholar
  • 28 Yu A S, Keefe E B. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence? (editorial).  Am J Gastroenterol. 2003;  98 955-956
    CrossrefPubMedGoogle Scholar
  • 29 Clinical Practice Committee AGA . AGA medical position statement: evaluation of liver chemistry tests.  Gastroenterology. 2003;  123 1364-1366
    PubMedGoogle Scholar
  • 30 Mofrad P, Contos M J, Haque M et al.. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.  Hepatology. 2003;  37 1286-1292
    CrossrefPubMedGoogle Scholar
  • 31 Mulhall B P, Ong J P, Younossi Z M. Non-alcoholic fatty liver disease: an overview.  J Gastroenterol Hepatol. 2002;  17 1136-1143
    CrossrefPubMedGoogle Scholar
  • 32 Hilden M, Christoffersen P, Juhl E, Dalgaard J B. Liver histology in a “normal” population-examinations of 503 consecutive fatal traffic casualties.  Scand J Gastroenterol. 1977;  12 593-597
    PubMedGoogle Scholar
  • 33 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.  Hepatology. 1990;  12 1106-1110
    CrossrefPubMedGoogle Scholar
  • 34 Charlton M, Kasparova P, Weston S et al.. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.  Liver Transpl. 2001;  7 608-614
    CrossrefPubMedGoogle Scholar
  • 35 Youssef W I, McCullough A J. Diabetes mellitus, obesity, and hepatic steatosis.  Semin Gastrointest Dis. 2002;  13 17-30
    PubMedGoogle Scholar
  • 36 Marchesini G, Bugianesi E, Forlani G et al.. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.  Hepatology. 2003;  37 917-923
    CrossrefPubMedGoogle Scholar
  • 37 Roberts E A. Steatohepatitis in children.  Best Pract Res Clin Gastroenterol. 2002;  16 749-765
    CrossrefPubMedGoogle Scholar
  • 38 Caldwell S H, Oelsner D H, Iezzoni J C et al.. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.  Hepatology. 1999;  29 664-669
    CrossrefPubMedGoogle Scholar
  • 39 Bacon B R, Farahvash M J, Janney C G, Neuschwandertetri B A. Nonalcoholic steatohepatitis-an expanded clinical entity.  Gastroenterology. 1994;  107 1103-1109
    PubMedGoogle Scholar
  • 40 Chitturi S, Farrell G C. Etiopathogenesis of nonalcoholic steatohepatitis.  Semin Liver Dis. 2001;  21 27-41
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Farrell G C. Drugs and steatohepatitis.  Semin Liver Dis. 2002;  22 185-194
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Garcia-Monzon C, Fernandez-Bermejo M. A wider view of diagnostic criteria of nonalcoholic steatohepatitis (letter to the editor).  Gastroenterology. 2002;  122 840-841
    PubMedGoogle Scholar
  • 43 Garcia-Monzon C, Martin-Perez E, Lo Iacono O et al.. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity.  J Hepatol. 2000;  33 716-724
    CrossrefPubMedGoogle Scholar
  • 44 Angulo P. Nonalcoholic fatty liver disease.  N Engl J Med. 2002;  346 1221-1231
    CrossrefPubMedGoogle Scholar
  • 45 Neuschwander-Tetri B A. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis.  Curr Gastroenterol Rep. 2002;  4 31-36
    CrossrefPubMedGoogle Scholar
  • 46 Skelly M M, James P D, Ryder S D. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology.  J Hepatol. 2001;  35 195-199
    CrossrefPubMedGoogle Scholar
  • 47 Marceau P, Biron S, Hould F S et al.. Liver pathology and the metabolic syndrome X in severe obesity.  J Clin Endocrinol Metab. 1999;  84 1513-1517
    CrossrefPubMedGoogle Scholar
  • 48 Cortez-Pinto H, Camilo M E, Baptista A, De Oliveira A G, De Moura M C. Non-alcoholic fatty liver: another feature of the metabolic syndrome?.  Clin Nutr. 1999;  18 353-358
    PubMedGoogle Scholar
  • 49 Marchesini G, Brizi M, Morselli-Labate A M et al.. Association of nonalcoholic fatty liver disease with insulin resistance.  Am J Med. 1999;  107 450-455
    Google Scholar
  • 50 Marchesini G, Brizi M, Bianchi G et al.. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.  Diabetes. 2001;  50 1844-1850
    CrossrefPubMedGoogle Scholar
  • 51 Pagano G, Pacini G, Musso G et al.. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.  Hepatology. 2002;  35 367-372
    CrossrefPubMedGoogle Scholar
  • 52 Chitturi S, Abeygunasekera S, Farrell G C et al.. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome.  Hepatology. 2002;  35 373-379
    CrossrefPubMedGoogle Scholar
  • 53 Youssef W I, McCullough A J. Steatohepatitis in obese individuals (review).  Best Pract Res Clin Gastroenterol. 2002;  16 733-747
    CrossrefPubMedGoogle Scholar
  • 54 Neuschwander-Tetri B A, Brunt E M, Wehmeier K R, Oliver D, Bacon B R. Improved nonalcoholic steatohepatitis following 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.  Hepatology. 2003;  38 1008-1017
    CrossrefPubMedGoogle Scholar
  • 55 Neuschwander-Tetri B A, Brunt E M, Wehmeier K R et al.. Interim results of a pilot study demonstrating the early effects of the PPAR-g ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.  J Hepatol. 2003;  38 434-440
    CrossrefPubMedGoogle Scholar
  • 56 Marchesini G, Brizi M, Bianchi G et al.. Metformin in non-alcoholic steatohepatitis.  Lancet. 2001;  358 893-894
    CrossrefPubMedGoogle Scholar
  • 57 Caldwell S H, Hespenheide E E, Redick J A et al.. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.  Am J Gastroenterol. 2001;  96 519-525
    CrossrefPubMedGoogle Scholar
  • 58 Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis.  Semin Liver Dis. 2001;  21 57-69
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Day C P, Saksena S. Nonalcoholic steatohepatitis: definitions and pathogenesis.  J Gastroenterol Hepatol. 2002;  17 S377-S384
    CrossrefPubMedGoogle Scholar
  • 60 Day C P. Pathogenesis of steatohepatitis.  Best Pract Res Clin Gastroenterol. 2002;  16 663-678
    CrossrefPubMedGoogle Scholar
  • 61 Lebovitz H E. The relationship of obesity to the metabolic syndrome.  Int J Clin Pract Suppl. 2003;  134 18-27
    PubMedGoogle Scholar
  • 62 Paradis V, Perlemuter G, Bonvoust F et al.. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis.  Hepatology. 2001;  34 738-744
    CrossrefPubMedGoogle Scholar
  • 63 Leclercq I A, Farrell G C, Schriemer R, Robertson G R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury.  J Hepatol. 2002;  37 206-213
    CrossrefPubMedGoogle Scholar
  • 64 Angulo P, Lindor K D. Treatment of nonalcoholic fatty liver: present and emerging therapies.  Semin Liver Dis. 2001;  21 81-88
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Angulo P, Lindor K D. Treatment of non-alcoholic steatohepatitis.  Best Pract Res Clin Gastroenterol. 2002;  16 797-810
    CrossrefPubMedGoogle Scholar
  • 66 O'Brien P E, Dixon J B. The extent of the problem of obesity.  Am J Surg. 2002;  184 4S-8S
    CrossrefPubMedGoogle Scholar
  • 67 Korner J, Leibel R L. To eat or not to eat-how the gut talks to the brain.  N Engl J Med. 2003;  349 926-928
    CrossrefPubMedGoogle Scholar
  • 68 McCullough A J, Falck-Ytter Y. Body composition and hepatic steatosis as precursors for fibrotic liver disease.  Hepatology. 1999;  29 1328-1330
    CrossrefPubMedGoogle Scholar
  • 69 Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones.  Trends Endocrinol Metab. 2003;  14 137-145
    PubMedGoogle Scholar
  • 70 Prins J B. Adipose tissue as an endocrine organ.  Best Pract Res Clin Endocrinol Metab. 2002;  16 639-651
    CrossrefPubMedGoogle Scholar
  • 71 Kern P A, Di Gregorio G B, Lu T, Rassouli N, Ranganathan G. Adiponectin exprssion from human adipose tissue. Relation to obesity, insulin resistance, and tumor necrosis factor-α expression.  Diabetes. 2003;  52 1779-1785
    CrossrefPubMedGoogle Scholar
  • 72 Stumvoll M. Thiazolidinediones-some recent developments.  Expert Opin Investig Drugs. 2003;  12 1179-1187
    CrossrefPubMedGoogle Scholar
  • 73 Das U N. Is metabolic syndrome X an inflammatory condition? (Review).  Exp Biol Med (Maywood). 2002;  227 989-997
    PubMedGoogle Scholar
  • 74 Xu A, Wang Y, Keshaw H et al.. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.  J Clin Invest. 2003;  112 91-100
    CrossrefPubMedGoogle Scholar
  • 75 Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis.  Hepatology. 2003;  38 244-251
    PubMedGoogle Scholar
  • 76 Ludwig J, McGill D B, Lindor K D. Review: nonalcoholic steatohepatitis.  J Gastroenterol Hepatol. 1997;  12 398-403
    CrossrefPubMedGoogle Scholar
  • 77 Lee R G. Nonalcoholic steatohepatitis: a study of 49 patients.  Hum Pathol. 1989;  20 594-598
    CrossrefPubMedGoogle Scholar
  • 78 Diehl A M, Goodman Z, Ishak K G. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury.  Gastroenterology. 1988;  95 1056-1062
    PubMedGoogle Scholar
  • 79 Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis.  Am J Gastroenterol. 1987;  82 650-654
    PubMedGoogle Scholar
  • 80 Brunt E M. Alcoholic and nonalcoholic steatohepatitis.  Clin Liver Dis. 2002;  6 399-420
    CrossrefPubMedGoogle Scholar
  • 81 Brunt E M, Tiniakos D G. Pathology of steatohepatitis (review).  Best Pract Res Clin Gastroenterol. 2002;  16 691-707
    CrossrefPubMedGoogle Scholar
  • 82 Burt A D, Mutton A, Day C P. Diagnosis and interpretation of steatosis and steatohepatitis.  Semin Diagn Pathol. 1998;  15 246-258
    PubMedGoogle Scholar
  • 83 Garg A, Misra A. Hepatic steatosis, insulin resistance and adipose tissue disorders (editorial).  J Clin Endocrinol Metab. 2002;  87 3019-3022
    CrossrefPubMedGoogle Scholar
  • 84 Ishak K G. Light microscopic morphology of viral hepatitis.  Am J Clin Pathol. 1976;  65 787-827
    PubMedGoogle Scholar
  • 85 Natori S, Rust C, Stadheim L M et al.. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis.  J Hepatol. 2001;  34 248-253
    CrossrefPubMedGoogle Scholar
  • 86 Ziol M, Tepper M, Lohez M et al.. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis.  J Hepatol. 2001;  34 254-260
    CrossrefPubMedGoogle Scholar
  • 87 Canbay A, Tamir P, Torok N J et al.. Apoptotic body engulfment by a human stellate cell line is profibrogenic.  Lab Invest. 2003;  83 655-663
    CrossrefPubMedGoogle Scholar
  • 88 Feldstein A E, Canbay A, Angulo P et al.. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.  Gastroenterology. 2003;  125 437-443
    CrossrefPubMedGoogle Scholar
  • 89 Nanki T, Koike R, Miyasaka N. Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis (letter to editor).  Am J Gastroenterol. 1999;  94 3379
    PubMedGoogle Scholar
  • 90 Dourakis S P, Sevastinaos V A, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy (letter to editor).  Am J Gastroenterol. 2002;  97 1074-1075
    CrossrefPubMedGoogle Scholar
  • 91 Caldwell S H, Hespenheide E E. Subacute liver failure in obese women.  Am J Gastroenterol. 2002;  97 2058-2062
    CrossrefPubMedGoogle Scholar
  • 92 Brunt E M, Ramrakhiani S, Cordes B G et al.. Concurrence of histologic features of steathepatitis with other forms of chronic liver disease.  Mod Pathol. 2003;  16 49-56
    CrossrefPubMedGoogle Scholar
  • 93 Brunt E M, Tiniakos D G. Steatosis, steatohepatitis: review of effects on chronic hepatitis C.  Current Hepatitis Reports. 2002;  1 38-44
    PubMedGoogle Scholar
  • 94 Clouston A D, Powell E E. Interaction of non-alcoholic fatty liver disease with other liver diseases.  Best Pract Res Clin Gastroenterol. 2002;  16 767-781
    CrossrefPubMedGoogle Scholar
  • 95 Ong J P, Younossi Z M, Speer C et al.. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease.  Liver. 2001;  21 266-271
    CrossrefPubMedGoogle Scholar
  • 96 Washington K, Wright K, Shyr Y et al.. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver.  Hum Pathol. 2000;  31 822-828
    CrossrefPubMedGoogle Scholar
  • 97 Cortez-Pinto H, Baptista A, Camilo M E, de Moura M C. Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis.  Hepatogastroenterol. 2001;  48 87-90
    PubMedGoogle Scholar
  • 98 Denk H, Stumptner C, Zatloukal K. Mallory bodies revisited.  J Hepatol. 2000;  32 689-702
    CrossrefPubMedGoogle Scholar
  • 99 Ludwig J, McGill D B, Lindor K D. Nonalcoholic steatohepatitis.  J Gastroenterol Hepatol. 1997;  12 398-403
    CrossrefPubMedGoogle Scholar
  • 100 Brunt E M, Janney C G, Di Bisceglie A M, Neuschwander-Tetri B A, Bacon B R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.  Am J Gastroenterol. 1999;  94 2467-2474
    CrossrefPubMedGoogle Scholar
  • 101 Stumptner C, Fuchsbichler A, Heid H, Zatloukal K, Denk H. Mallory body-a disease-associated type of sequestosome.  Hepatology. 2002;  35 1053-1062
    CrossrefPubMedGoogle Scholar
  • 102 Savas M C, Koruk M, Pirim I et al.. Serum ubiquitin levels in patients with nonalcoholic steatohepatitis.  Hepatogastroenterology. 2003;  50 738-741
    PubMedGoogle Scholar
  • 103 Teli M R, Day C P, Burt A D, Bennett M J, James O F. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver.  Lancet. 1995;  346 987-990
    CrossrefPubMedGoogle Scholar
  • 104 Caldwell S H, Swerdlow R H, Khan E M et al.. Mitochondrial abnormalities in non-alcoholic steatohepatitis.  J Hepatol. 1999;  31 430-434
    CrossrefPubMedGoogle Scholar
  • 105 Sanyal A J, Campbell-Sargent C, Mirshahi F et al.. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.  Gastroenterology. 2001;  120 1183-1192
    CrossrefPubMedGoogle Scholar
  • 106 George D K, Goldwurm S, MacDonald G A et al.. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.  Gastroenterology. 1998;  114 311-318
    CrossrefPubMedGoogle Scholar
  • 107 Younossi Z M, Gramlich T, Bacon B R et al.. Hepatic iron and nonalcoholic fatty liver disease.  Hepatology. 1999;  30 847-850
    CrossrefPubMedGoogle Scholar
  • 108 Bonkovsky H L, Jawaid Q, Tortorelli K et al.. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis.  J Hepatol. 1999;  31 421-429
    CrossrefPubMedGoogle Scholar
  • 109 Chitturi S, Weltman M, Farrell G C et al.. HFE Mutations, hepatic iron, and fibrosis: Ethnic-specific association of NASH with C282Y but not with fibrotic severity.  Hepatology. 2002;  36 142-149
    CrossrefPubMedGoogle Scholar
  • 110 Cortez-Pinto H, Baptista A, Camilo M E et al.. Nonalcoholic steatohepatitis-clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients.  Dig Dis Sci. 1996;  41 172-179
    PubMedGoogle Scholar
  • 111 Abdelmalek M, Angulo P, Jorgensen R A, Sylvestre P B, Lindor K. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.  Am J Gastroenterol. 2001;  96 2711-2717
    Google Scholar
  • 112 Laurin J, Lindor K D, Crippin J S et al.. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis-a pilot study.  Hepatology. 1996;  23 1464-1467
    CrossrefPubMedGoogle Scholar
  • 113 Andersen T, Gluud C, Franzmann M-B, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects.  J Hepatol. 1991;  12 224-229
    CrossrefPubMedGoogle Scholar
  • 114 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology. 1999;  30 1356-1362
    CrossrefPubMedGoogle Scholar
  • 115 Ratziu V, Giral P, Charlotte F et al.. Liver fibrosis in overweight patients.  Gastroenterology. 2000;  118 1117-1123
    CrossrefPubMedGoogle Scholar
  • 116 Dixon J B, Bhatal P S, O'Brien P E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.  Gastroenterology. 2001;  121 91-100
    CrossrefPubMedGoogle Scholar
  • 117 Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Nonalcoholic steatohepatitis: risk factors for liver fibrosis.  Hepatol Res. 2002;  24 429-438
    PubMedGoogle Scholar
  • 118 Evans C DJ, Oien K A, MacSween R NM, Mills P R. Nonalcoholic steatohepatitis: a common cause of advanced liver injury?.  J Clin Pathol. 2002;  55 689-692
    CrossrefPubMedGoogle Scholar
  • 119 Brunt E M. Grading and staging the histopathologcial lesions of chronic hepatitis: the Knodell histology activity index and beyond.  Hepatology. 2000;  31 241-246
    CrossrefPubMedGoogle Scholar
  • 120 Abdelmalek M, Ludwig J, Lindor K D. Two cases from the spectrum of nonalcoholic steatohepatitis.  J Clin Gastroenterol. 1995;  20 127-130
    PubMedGoogle Scholar
  • 121 Contos M J, Cales W, Sterling R K et al.. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis.  Liver Transpl. 2001;  7 363-373
    CrossrefPubMedGoogle Scholar
  • 122 Shimada M, Hashimoto E, Taniai M et al.. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.  J Hepatol. 2002;  37 154-160
    CrossrefPubMedGoogle Scholar
  • 123 Hui J M, Kench J G, Chitturi S et al.. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.  Hepatology. 2003;  38 420-427
    PubMedGoogle Scholar
  • 124 Calle E E, Rodriguez C, Walker-Thurmond K, Thun M J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.  N Engl J Med. 2003;  348 1625-1638
    CrossrefPubMedGoogle Scholar
  • 125 Nair S, Mason A, Eason J, Loss G, Perillo R P. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?.  Hepatology. 2002;  36 150-155
    CrossrefPubMedGoogle Scholar
  • 126 Marrero J A, Fontana R J, Su G L et al.. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.  Hepatology. 2002;  36 1349-1354
    CrossrefPubMedGoogle Scholar
  • 127 Ratziu V, Bonyhay L, Di Martino V et al.. Survival, liver failure and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.  Hepatology. 2002;  35 1485-1493
    CrossrefPubMedGoogle Scholar
  • 128 Balkau B, Kahn H S, Courbon D, Eschwege E, Ducimetiere P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites.  Diabetes Care. 2001;  24 843-849
    PubMedGoogle Scholar
  • 129 Yang S, Lin H Z, Hwang J, Chacko V P, Diehl A M. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?.  Cancer Res. 2001;  61 5016-5023
    PubMedGoogle Scholar

Elizabeth M BruntM.D. 

4th Floor FDT, Saint Louis University Hospital

3635 Vista Avenue at Grand Boulevard

St. Louis, MO 63110

Email: bruntem@slu.edu

      >